How to access Nucala from India — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Indian patient with severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), or chronic rhinosinusitis with nasal polyps (CRSwNP) may receive a prescription for Nucala (mepolizumab) from their treating pulmonologist, allergist, rheumatologist, or ENT specialist. Nucala is FDA-approved across all four indications and manufactured by GSK. It is an anti-IL-5 monoclonal antibody — binding the IL-5 ligand rather than its receptor — and was the first severe-asthma biologic approved for the eosinophilic phenotype. In India, Nucala is available through some tertiary hospital pharmacies, but availability of the autoinjector presentation, and institutional procurement timing for the monthly maintenance cadence, can make the CDSCO personal-use import pathway the cleaner route for families wanting a predictable calendar.

This guide explains the pathway, documentation your physician prepares, indicative timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Nucala is a humanised IgG1 monoclonal antibody that binds IL-5, preventing IL-5 from engaging its receptor on eosinophils. The result is reduced eosinophil production and survival, reduced airway and tissue eosinophilia, and reduced exacerbations in eosinophilic disease. Dosing is 100 mg subcutaneously every four weeks for severe asthma, EGPA, and CRSwNP (300 mg every four weeks for HES). Eligibility typically requires documented eosinophilic phenotype (blood eosinophils, tissue eosinophils for EGPA/HES), recurrent exacerbations or active disease on baseline therapy, and a specialist's assessment of fit versus other anti-IL-5-class or phenotype-targeted biologics. Your physician confirms the indication, prior therapy history, and monitoring plan.

Is Nucala legally importable into India?

Yes — through the Central Drugs Standard Control Organisation (CDSCO) personal-use / named-patient import framework under Rule 36 and related provisions of the Drugs and Cosmetics Rules. The mechanism permits import of up to three months' personal supply for a named patient under a registered medical practitioner's prescription, with customs clearance supported by the prescription, the physician's letter, and product documentation. It has been used routinely for specialty biologics including severe-asthma agents when local supply, presentation, or institutional timing is not clinically workable.

How the pathway works, step by step

1. Consultation with your treating specialist. Diagnosis confirmation, phenotype workup (eosinophils, IgE, specific tissue biopsy for EGPA/HES), prior therapy history, and rationale for Nucala.
2. Baseline screening. Parasitic infection screening (IL-5 blockade can unmask helminth infection), vaccination status, and baseline labs per labeling.
3. Prescription and import letter. Your physician issues the prescription and a clinical letter describing indication, dosing schedule, and personal-use rationale.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Nucala from authorised distribution under DSCSA.
5. Cold-chain shipment to India. Nucala ships under validated 2-8 °C conditions with temperature logging; Reserve Meds handles customs documentation with the importing agent.
6. Arrival and administration. First dose administered under physician observation; subsequent monthly doses administered by clinician or, after training, by the patient or caregiver at home via prefilled syringe or autoinjector.

What documentation your physician needs

• Clinical rationale letter confirming diagnosis, phenotype, and Nucala as the indicated biologic
• Verification of Medical Council of India / NMC registration
• Blood eosinophil count and other phenotype data
• For EGPA/HES: tissue biopsy or diagnostic workup supporting the indication
• Planned dosing schedule (100 mg or 300 mg monthly)
• Patient identifier and residential address for import clearance

Reserve Meds provides a physician documentation kit that bundles the templates CDSCO and customs expect to see for anti-IL-5-class biologic personal imports.

Typical costs and indicative timing

Nucala's US cash-pay drug-only reference range in 2026 sits at roughly USD 3,800-5,000 per 100 mg SC dose (monthly), with higher cost for the 300 mg HES regimen. International cold-chain logistics, CDSCO documentation handling, customs clearance, and concierge coordination are quoted separately. Reserve Meds issues a full transparent delivered quote at intake so your family sees one landed number before committing. These ranges are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 7-14 days from the moment complete documentation is in hand. Maintenance doses ship monthly on a rolling calendar.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Nucala specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from authorised channels.
• Documentation. Regulatory package for your physician, CDSCO import documentation, and customs-clearance support.
• Logistics. Validated 2-8 °C cold-chain shipment with temperature logging.
• Concierge case lead. A named point of contact coordinating monthly refills.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating specialist. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with a valid prescription and supporting physician letter. See our trust and compliance page for our methodology.

How does Nucala compare with Fasenra? Both are anti-IL-5-pathway biologics for severe eosinophilic asthma, but Nucala binds the IL-5 ligand and Fasenra binds the receptor (IL-5Rα) and depletes eosinophils via ADCC. Nucala's cadence is every four weeks; Fasenra's maintenance is every eight weeks after loading. Nucala has broader FDA indications (EGPA, HES, CRSwNP in addition to asthma). Your physician chooses based on phenotype, indication, and cadence.

Can my child receive Nucala? The FDA approval in severe asthma covers patients 6 years and older. EGPA, HES, and CRSwNP labeling varies by age; your specialist confirms eligibility.

What about parasitic infection risk? IL-5 is involved in helminth defence; screening for pre-existing parasitic infection is recommended before starting Nucala per labeling. Your physician manages this screening.

Will private insurance cover this? Cash-pay is the default. Some Indian private insurers and corporate plans consider named-patient imports case by case; we supply documentation for your submission but do not process claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Nucala coordination in India.

Add me to the Nucala waitlist

---

Examples and timings above are composite illustrations drawn from published sources and typical personal-use import patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.